Hien D Liu
Overview
Explore the profile of Hien D Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freeman C, Noble J, Menges M, Villanueva R, Nakashima J, Figura N, et al.
Blood
. 2024 Dec;
PMID: 39652773
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a breakthrough treatment for relapsed and refractory multiple myeloma (RRMM). However, these products are complex to deliver and alternative options are...
2.
Hoogland A, Barata A, Li X, Irizarry-Arroyo N, Jain M, Welniak T, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1219.e1-1219.e11.
PMID: 39306278
Chimeric antigen receptor (CAR) T-cell therapy has transformed survival outcomes in patients with relapsed and refractory large B-cell lymphoma (LBCL), but it is associated with a variety of side effects....
3.
Zhang Y, Rose A, Khadka S, Cao B, Eatrides J, Saeed H, et al.
Transplant Cell Ther
. 2024 May;
30(9):887.e1-887.e9.
PMID: 38740140
Nodal peripheral T cell lymphomas (PTCLs) are challenging subsets of non-Hodgkin lymphomas characterized by their heterogeneity and aggressive clinical behavior. Given the mixed outcomes reported in previous studies, the efficacy...
4.
Bray K, Lynde C, Vu T, Patterson A, Reich R, Mason T, et al.
J Clin Apher
. 2023 Jul;
38(6):654-663.
PMID: 37522733
Symptoms of hypocalcemia are reported in up to 50% of patients undergoing leukapheresis procedures. There is no set standard of practice for administering calcium supplementation in the prevention or treatment...
5.
Logue J, Peres L, Hashmi H, Colin-Leitzinger C, Shrewsbury A, Hosoya H, et al.
Blood Adv
. 2022 Aug;
6(24):6109-6119.
PMID: 35939783
Idecabtagene vicleucel (ide-cel) was FDA-approved in March 2021 for the treatment of relapsed/refractory multiple myeloma after 4 lines of therapy. On the KarMMa trial, grade ≥ 3 cytopenias and infections...
6.
Liu H, Su L, Winters J, Thibodeaux S, Park Y, Wu Y, et al.
Cytotherapy
. 2022 Apr;
24(9):916-922.
PMID: 35398001
Background Aims: This white paper was developed to provide leukapheresis guidance for the collection of mononuclear cells from adult and pediatric patients who are destined for immune effector cell (IEC)...
7.
Lynes J, Rubino S, Rogers A, Gaballa S, Liu H, Arrington J, et al.
J Neurol Surg Rep
. 2022 Mar;
83(1):e19-e22.
PMID: 35273899
Spontaneous spinal subdural hematomas (SSH) are rare occurrences that can occur most commonly secondary to vascular malformations or coagulopathies. Only a small fraction of spontaneous SSHs are caused by acquired...
8.
Thibodeaux S, Aqui N, Park Y, Schneiderman J, Su L, Winters J, et al.
J Clin Apher
. 2022 Jan;
37(3):223-236.
PMID: 35085413
Background: Chimeric antigen receptor T (CAR-T) cell successes have encouraged continued clinical study. Apheresis collection of starting material for CAR-T cell therapy product manufacturing is critical but described approaches suggest...
9.
Figura N, Robinson T, Sim A, Wang X, Cao B, Chavez J, et al.
Int J Radiat Oncol Biol Phys
. 2021 Jul;
111(5):1145-1154.
PMID: 34242714
Purpose: Chimeric antigen receptor T-cell (CAR T) therapy is capable of eliciting durable responses in patients with relapsed/refractory (R/R) lymphomas. However, most treated patients relapse. Patterns of failure after CAR...
10.
Elmariah H, Naqvi S, Kim J, Nishihori T, Mishra A, Perez L, et al.
Bone Marrow Transplant
. 2021 Mar;
56(7):1683-1690.
PMID: 33658647
Higher infused total nucleated cell dose (TNC) in allogeneic bone marrow transplant (BMT) with post-transplant cyclophosphamide (PTCy) is associated with improved overall survival. As many centers prefer peripheral blood stem...